Omeros (NASDAQ:OMER) Receives Buy Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Omeros (NASDAQ:OMER) in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a $36.00 price target on the biopharmaceutical company’s stock.

OMER has been the topic of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a research note on Wednesday, October 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a report on Wednesday, October 15th. Wall Street Zen upgraded Omeros from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. HC Wainwright boosted their price target on Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday. Finally, WBB Securities reaffirmed a “strong-buy” rating and issued a $45.00 price objective on shares of Omeros in a research note on Wednesday, October 15th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $40.33.

Omeros Stock Down 4.5%

OMER stock opened at $13.45 on Thursday. Omeros has a 52 week low of $2.95 and a 52 week high of $17.65. The business has a 50-day simple moving average of $10.48 and a 200 day simple moving average of $6.57. The company has a market cap of $953.61 million, a PE ratio of -6.66 and a beta of 2.38.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.39. On average, analysts anticipate that Omeros will post -3.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC boosted its position in Omeros by 9.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 31,728 shares of the biopharmaceutical company’s stock worth $545,000 after buying an additional 2,631 shares during the period. Harbour Investments Inc. increased its position in Omeros by 46.1% in the 2nd quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 4,251 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Omeros by 113.1% during the third quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 5,677 shares during the period. Rhumbline Advisers lifted its holdings in shares of Omeros by 7.1% during the third quarter. Rhumbline Advisers now owns 105,873 shares of the biopharmaceutical company’s stock worth $434,000 after purchasing an additional 7,048 shares during the period. Finally, Cypress Capital Group grew its stake in shares of Omeros by 20.7% in the second quarter. Cypress Capital Group now owns 42,000 shares of the biopharmaceutical company’s stock worth $126,000 after purchasing an additional 7,200 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

More Omeros News

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: HC Wainwright raised its price target for OMER to $40 (from $20) and carries a Buy rating, signaling analysts see substantial upside versus current levels. This upgrade can support bullish sentiment and buying interest. HC Wainwright raises OMER PT to $40
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating and set a $36 price target, another analyst vote of confidence that could attract momentum buyers. D. Boral reaffirms Buy on OMER
• Positive Sentiment: Omeros showed a post-close/after-hours move higher in recent trading, indicating intraday volatility and that some investors are reacting positively to recent news flows. After-hours strength can sometimes precede renewed buying next session. After-hours move coverage
• Neutral Sentiment: Needham maintained a Hold rating (balanced risk/reward view and gradual ramp for Yartemlea), which tempers the bullish analyst actions and adds a cautious voice to the analyst mix. Needham Hold note
• Neutral Sentiment: Omeros released details on FDA approval and commercialization plans for YARTEMLEA; investors are parsing launch timelines, distribution, and payer strategy — important for revenue visibility but not an immediate binary outcome. FDA approval/commercialization transcript
• Neutral Sentiment: Omeros announced Yartemlea will be priced at $36,000 per single-dose vial. While the price point supports revenue per dose, it also raises potential payer/access questions that could delay uptake — making near-term commercial performance uncertain. Pricing announcement

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.